Oncology

Acute diarrhea during chemoradiotherapy for anal cancer is significantly more likely among patients treated with 5-fluorouracil (5-FU) or capecitabine compared with those receiving cisplatin or radiotherapy alone, according to new findings.

Overall survival in the Asia cohort of the Phase III MARIPOSA study has been reported to favor amivantamab combined with lazertinib compared with osimertinib monotherapy in patients with epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer (NSCLC).

Timely initiation of postoperative radiation therapy (PORT) within 6 weeks of surgery is a critical factor in improving outcomes for patients with head and neck squamous cell carcinoma.

Ocular toxicities are an emerging challenge in the management of gynecologic cancers treated with antibody drug conjugates, with new research outlining prevention and care strategies to safeguard patient outcomes.

A new real-world study has mapped the treatment landscape for mantle cell lymphoma (MCL) in Japan, highlighting common patient characteristics, therapeutic strategies, and ongoing gaps in efficacy and quality of life outcomes.

Confirmatory testing for men with low-risk prostate cancer increased steadily in recent years, but a payment incentive program was not linked to a statistically significant improvement in its use, according to a large cohort study.

Greater familiarity among surgical teams significantly improves outcomes in renal, bladder, and prostate cancer procedures, according to a new study assessing team membership and cohesion.

TAR-200, an investigational intravesical drug-releasing system delivering sustained gemcitabine, demonstrated high response rates and durable outcomes in patients with bacillus Calmette-Guérin (BCG)–unresponsive high-risk non–muscle-invasive bladder cancer (NMIBC), according to results from the Phase IIb SunRISe-1 study.